Idiopathic Pulmonary Arterial Hypertension Clinical Trial
Official title:
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets. Funding Source - FDA OOPD
Pulmonary arterial hypertension (PAH) is an orphan disease with a delayed diagnosis and markedly elevated mortality from right heart failure. Despite nearly a dozen FDA-approved drugs for PAH, median survival is only seven years. All approved therapies target one of three vasodilatory pathways, and none are disease modifying. This study has two objectives: 1) Understand dynamic and static relationships between molecular markers and PAH progression and resilience; 2) Identify molecular features of PAH risk and resilience in individuals harboring a PAH-causing mutation. It is unknown why some at risk individuals develop PAH and others do not. BMPR2 mutations are present in about 30% of patients with PAH but clinical penetrance is only 20%. Unaffected BMPR2 mutation carriers (UMCs) are a unique and understudied population that may also provide clues to disease trajectory in patients with clinical PAH. Longitudinal natural history studies with molecular profiling in PAH are lacking. Most molecular profiling studies in PAH are cross-sectional which limits understanding of how disease progression and disease markers relate over time. The Investigators propose a strategy of dense clinical and molecular phenotyping at multiple timepoints to overcome inferential limitations of cross-sectional studies. This application will leverage the clinical and research infrastructure built at Vanderbilt over the past 35 years in our study of PAH patients. The investigators share an extensive published record of recruiting patients with this rare disease and related UMCs. The Investigators hypothesize that a comprehensive understanding of risk and resilience over time in patients and genetically susceptible individuals will provide insight into disease severity and identify novel therapeutic targets in patients with PAH. Aim 1 will identify static and dynamic molecular features of disease progression and resilience. 1a: Perform serial clinical, proteomic, and gene expression profiling in HPAH, IPAH, and healthy controls 3 times over 4 years. Bioinformatic and network medicine analyses will identify proteins and RNAs associated with changes in clinical outcomes, functional capacity, and RV function in the parent cohort and two external validation cohorts.1b: Test whether adding molecular risk/resilience markers will improve the performance of a widely used PAH risk prediction tool (REVEAL 2.0 Risk Score). Aim 2 will identify the clinical and molecular factors that promote resilience and susceptibility to PAH in a longitudinal cohort of UMCs. UMCs will undergo serial clinical and molecular phenotyping as in Aim 1. Proteins/genes that mirror PAH are "risk factors" and those that mirror a healthy population are "resilience factors". Explanatory models will be developed and tested in validation cohorts. The Investigators will test UMC risk and resilience features for associations with clinical outcomes in PAH patients and risk prediction performance. These studies will identify signatures of risk and resilience to PAH progression and penetrance, offering an initial step toward personalizing care and surveillance guided by biologic data. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01884051 -
Hormonal, Metabolic, and Signaling Interactions in PAH
|
||
Completed |
NCT00626028 -
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
|
Phase 3 | |
Completed |
NCT02790450 -
Acute Effects of Benzbromaron on the Pulmonary Circulation
|
Phase 2 | |
Completed |
NCT01590108 -
The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT05493371 -
Empagliflozin in Pulmonary Arterial Hypertension
|
Phase 2 | |
Recruiting |
NCT03933579 -
The PAH Platform for Deep Phenotyping in Korean Subjects
|
||
Completed |
NCT01613287 -
Proof of Concept Study of IMMUNOadsorption Therapy in Patients With Idiopathic Pulmonary Arterial Hypertension
|
N/A | |
Recruiting |
NCT00372346 -
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
|
N/A | |
Withdrawn |
NCT01645826 -
Efficacy Study of Cardizem in Pulmonary Arterial Hypertension
|
N/A | |
Completed |
NCT00641836 -
Safety and Feasibility of Autologous Endothelial Progenitor Cells Transplantation in Patients With Idiopathic Pulmonary Arterial Hypertension
|
N/A | |
Not yet recruiting |
NCT06104228 -
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
|
Phase 2 | |
Recruiting |
NCT02959723 -
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies
|
N/A | |
Recruiting |
NCT01288651 -
Iron Deficiency In Pulmonary Hypertension
|
Phase 4 | |
Recruiting |
NCT05462574 -
Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)
|
||
Completed |
NCT02565030 -
Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome
|
||
Active, not recruiting |
NCT01246037 -
Beta-blockers in i-PAH
|
Phase 1/Phase 2 | |
Recruiting |
NCT01683981 -
Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate
|
Phase 0 | |
Completed |
NCT03069716 -
A Mobile Health Intervention in Pulmonary Arterial Hypertension
|
N/A | |
Completed |
NCT05767918 -
StratosPHere (Non-interventional Study)
|
||
Completed |
NCT00257413 -
Safety and Efficacy Study of Transplantation of EPCs to Treat Idiopathic Pulmonary Arterial Hypertension
|
N/A |